Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Prospective European Trial Explores Cancer-Nutrition Links Links

October 1, 2000
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 10
Volume 9
Issue 10

WASHINGTON-Size matters, especially in epidemiologic studies. The European Prospective Investigations into Cancer and Nutrition (EPIC) was founded on that principle in 1992, said Elio Riboli, MD, ScM, MPH.

WASHINGTON—Size matters, especially in epidemiologic studies. The European Prospective Investigations into Cancer and Nutrition (EPIC) was founded on that principle in 1992, said Elio Riboli, MD, ScM, MPH.

Since then, the EPIC researchers have recruited 484,000 subjects from nine European countries for a multicenter, prospective study of the relationship between dietary, genetic, metabolic, and lifestyle characteristics and the risk of cancer and cardiovascular disease.

Dr. Riboli, chief of the Nutrition and Cancer Unit of the International Agency for Research on Cancer, Lyon, France, described the research project at the 10th Annual Research Conference of the American Institute for Cancer Research (AICR).

“We know that a plant-based diet protects against cancers of the colorectum, stomach, upper aerodigestive tract, and possibly others,” Dr. Riboli said. “We also know that salty foods raise the risk of stomach cancer and that there is information suggesting that eating meat increases colorectal cancer risk. But we need to know more: Which foods? Which vegetables? What is their chemical and physical structure?”

In short, while “eat more fruits and vegetables” may be good advice for the public, more detailed information is needed to determine the role of nutrition in initiating or preventing the development of many cancers, he said.

An advantage of studying populations across Europe (in Denmark, France, Germany, Greece, Italy, the Netherlands, Spain, Sweden, and the United Kingdom) is that wide variations in cancer incidence and dietary practices can be explored.

For instance, Dr. Riboli said, the breast cancer rate in Scotland is four times higher than the rate in Sicily or southern Spain, while the stomach cancer rate is highest in central Spain and northern Italy and lowest in England.

The EPIC researchers have collected a detailed questionnaire from each study subject on diet, lifestyle, illness, medication use, physical activity, alcohol and tobacco use, reproductive and contraceptive history, and socioeconomic factors. Anthropometric measurements have also been taken.

The food questionnaire lists 150 to 300 food choices, and a more detailed inquiry into a 1-day “actual” diet taken from 7% of the respondents will cover 3,000 possible food descriptions and 700 recipes tailored for each country. “At worst,” Dr. Riboli quipped, “we can publish books of recipes, if we fail as cancer researchers.”

To date, the EPIC group has taken blood samples from 387,000 subjects. Blood from each subject is parceled out into 28 small (0.5 mL) plastic straws containing plasma, serum, buffy coat or red blood cells, and stored in liquid nitrogen for study over the next 10 to 15 years. The storage system is designed to withstand power outages as long as 4 months without refilling.

EPIC will use these stored biologic samples to measure biomarkers that will then be correlated with the 17,000 cases of cancer expected to occur in this cohort by 2002. Prediagnostic levels of steroid hormones, insulin-like growth factors, and other metabolic factors will be correlated with inherited genetic susceptibilities.

“We are trying to go beyond the black box of epidemiology and identify mechanisms that lead to cancers,” Dr. Riboli said. This may lead to answers to current puzzles such as whether levels of eicosapentaenoic acid (EPA) from fish oil are related to cancer risk. EPA levels have been shown to be higher in Denmark and lower among a group of vegetarians in Oxford, UK.

These biomarker studies may also lead to improved measurements of data collected on dietary questionnaires, whose accuracy has long been debated by nutrition researchers.

Articles in this issue

HER-2/neu Activation May Predict Breast Cancer Prognosis
Company Offers Computer-Aided Detection of Breast Cancer
Adjuvant Tamoxifen Equally Effective in Black and White Breast Cancer Patients
ASBD, an Interdisciplinary Group, Fights Breast Cancer
How Employers Can Help Caregivers in the Workplace
Only Slight Improvement in Hepatocellular Carcinoma Survival
New BRCA1 Mutations Found in Black and Hispanic Women
Study Shows Profile of At-Risk Elderly Lung Cancer Patients
Scientific Studies Support Strategies to Curb Nicotine Addiction
Smoking Declines Among High School Males, But Not Females
Cuts in Medicare Reimbursement for Cancer Drugs on Hold
New Chemoprevention Trials of COX-2 Inhibitors Underway
Panel to Recommend Changes to Cancer Act
NIH Adjuvant Therapy for Breast Cancer Panel to Address 7 Issues
Data Support Chemo for All Young Breast Cancer Patients
Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content
Advertisement

XTR008 achieved a higher ORR and improved QOL compared with high-dose octreotide long-acting repeatable in advanced GEP-NETs.

XTR008 Significantly Extends Progression-Free Survival in SSTR+ GEP-NETs

Sabrina Serani
October 18th 2025
Article

XTR008 achieved a higher ORR and improved QOL compared with high-dose octreotide long-acting repeatable in advanced GEP-NETs.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Giredestrant plus everolimus doubled the ORR and prolonged the DOR in patients with ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor.

Giredestrant Combo Improves Efficacy vs SOC in ER+, HER2- Breast Cancer

Silas Inman
October 18th 2025
Article

Giredestrant plus everolimus doubled the ORR and prolonged the DOR in patients with ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor.


Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.


Fruquintinib/Sintilimab Shows Promising PFS in Advancing RCC, 1L VEGFR TKI Therapy

Fruquintinib/Sintilimab Shows Promising PFS in Advancing RCC, 1L VEGFR TKI Therapy

Jax DiEugenio
October 18th 2025
Article

Fruquintinib plus sintilimab significantly enhanced PFS in advanced RCC offering a promising second-line treatment option.


Pimicotinib Yields Long-Term Response in Tenosynovial Giant Cell Tumor

Pimicotinib Yields Long-Term Response in Tenosynovial Giant Cell Tumor

Chris Ryan
October 18th 2025
Article

Pimicotinib shows promising long-term efficacy and safety for treating tenosynovial giant cell tumor, offering significant patient benefits in a recent trial.

Related Content
Advertisement

XTR008 achieved a higher ORR and improved QOL compared with high-dose octreotide long-acting repeatable in advanced GEP-NETs.

XTR008 Significantly Extends Progression-Free Survival in SSTR+ GEP-NETs

Sabrina Serani
October 18th 2025
Article

XTR008 achieved a higher ORR and improved QOL compared with high-dose octreotide long-acting repeatable in advanced GEP-NETs.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Giredestrant plus everolimus doubled the ORR and prolonged the DOR in patients with ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor.

Giredestrant Combo Improves Efficacy vs SOC in ER+, HER2- Breast Cancer

Silas Inman
October 18th 2025
Article

Giredestrant plus everolimus doubled the ORR and prolonged the DOR in patients with ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor.


Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.


Fruquintinib/Sintilimab Shows Promising PFS in Advancing RCC, 1L VEGFR TKI Therapy

Fruquintinib/Sintilimab Shows Promising PFS in Advancing RCC, 1L VEGFR TKI Therapy

Jax DiEugenio
October 18th 2025
Article

Fruquintinib plus sintilimab significantly enhanced PFS in advanced RCC offering a promising second-line treatment option.


Pimicotinib Yields Long-Term Response in Tenosynovial Giant Cell Tumor

Pimicotinib Yields Long-Term Response in Tenosynovial Giant Cell Tumor

Chris Ryan
October 18th 2025
Article

Pimicotinib shows promising long-term efficacy and safety for treating tenosynovial giant cell tumor, offering significant patient benefits in a recent trial.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.